Vascular calcification in CKD: New insights into its mechanisms
- PMID: 37269534
- DOI: 10.1002/jcp.31021
Vascular calcification in CKD: New insights into its mechanisms
Abstract
Vascular calcification (VC) is a common complication of chronic kidney disease (CKD) and contributes to an increased risk of cardiovascular morbidity and mortality. However, effective therapies are still unavailable at present. It has been well established that VC associated with CKD is not a passive process of calcium phosphate deposition, but an actively regulated and cell-mediated process that shares many similarities with bone formation. Additionally, numerous studies have suggested that CKD patients have specific risk factors and contributors to the development of VC, such as hyperphosphatemia, uremic toxins, oxidative stress and inflammation. Although research efforts in the past decade have greatly improved our knowledge of the multiple factors and mechanisms involved in CKD-related VC, many questions remain unanswered. Moreover, studies from the past decade have demonstrated that epigenetic modifications abnormalities, such as DNA methylation, histone modifications and noncoding RNAs, play an important role in the regulation of VC. This review seeks to provide an overview of the pathophysiological and molecular mechanisms of VC associated with CKD, mainly focusing on the involvement of epigenetic modifications in the initiation and progression of uremic VC, with the aim to develop promising therapies for CKD-related cardiovascular events in the future.
Keywords: VSMC phenotypic transition; chronic kidney disease; epigenetic modifications; noncoding RNAs; vascular calcification.
© 2023 Wiley Periodicals LLC.
Similar articles
-
CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.Atherosclerosis. 2018 Nov;278:49-59. doi: 10.1016/j.atherosclerosis.2018.08.046. Epub 2018 Aug 30. Atherosclerosis. 2018. PMID: 30253289 Review.
-
Advances in pharmacotherapy for hyperphosphatemia in renal disease.Expert Opin Pharmacother. 2015;16(17):2589-99. doi: 10.1517/14656566.2015.1092521. Epub 2015 Sep 16. Expert Opin Pharmacother. 2015. PMID: 26374200 Review.
-
Oxidative stress contributes to vascular calcification in patients with chronic kidney disease.J Mol Cell Cardiol. 2020 Jan;138:256-268. doi: 10.1016/j.yjmcc.2019.12.006. Epub 2019 Dec 19. J Mol Cell Cardiol. 2020. PMID: 31866376
-
Vascular Calcification: An Important Understanding in Nephrology.Vasc Health Risk Manag. 2020 May 12;16:167-180. doi: 10.2147/VHRM.S242685. eCollection 2020. Vasc Health Risk Manag. 2020. PMID: 32494148 Free PMC article. Review.
-
Mitochondria and vascular calcification in chronic kidney disease: Lessons learned from the past to improve future therapy.J Cell Physiol. 2022 Dec;237(12):4369-4396. doi: 10.1002/jcp.30891. Epub 2022 Oct 2. J Cell Physiol. 2022. PMID: 36183389 Review.
Cited by
-
Endothelial dysfunction in chronic kidney disease: a clinical perspective.Am J Physiol Heart Circ Physiol. 2025 Jul 1;329(1):H135-H153. doi: 10.1152/ajpheart.00908.2024. Epub 2025 May 27. Am J Physiol Heart Circ Physiol. 2025. PMID: 40423627 Free PMC article. Review.
-
Salvianolic acid B ameliorates vascular calcification in rats with chronic kidney disease combined with arteriovenous fistula by inhibiting BMP2/Smads signaling.Ren Fail. 2025 Dec;47(1):2542524. doi: 10.1080/0886022X.2025.2542524. Epub 2025 Aug 7. Ren Fail. 2025. PMID: 40775281 Free PMC article.
-
Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells.Cell Mol Life Sci. 2024 Nov 9;81(1):448. doi: 10.1007/s00018-024-05486-8. Cell Mol Life Sci. 2024. PMID: 39520538 Free PMC article.
-
Exploring the role of vascular frailty in understanding blood pressure variability and mortality risk among end-stage kidney disease patients undergoing hemodialysis.Clin Cardiol. 2024 May;47(5):e24281. doi: 10.1002/clc.24281. Clin Cardiol. 2024. PMID: 38738580 Free PMC article. No abstract available.
-
Histone deacetylase 9 promotes osteogenic trans-differentiation of vascular smooth muscle cells via ferroptosis in chronic kidney disease vascular calcification.Ren Fail. 2024 Dec;46(2):2422435. doi: 10.1080/0886022X.2024.2422435. Epub 2024 Nov 5. Ren Fail. 2024. PMID: 39500708 Free PMC article.
References
REFERENCES
-
- Adeney, K. L., Siscovick, D. S., Ix, J. H., Seliger, S. L., Shlipak, M. G., Jenny, N. S., & Kestenbaum, B. R. (2009). Association of serum phosphate with vascular and valvular calcification in moderate CKD. Journal of the American Society of Nephrology, 20, 381-387.
-
- Akers, J. C., Gonda, D., Kim, R., Carter, B. S., & Chen, C. C. (2013). Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. Journal of Neuro-Oncology, 113, 1-11.
-
- Alkagiet, S. & Tziomalos, K. (2017). Vascular calcification: The role of microRNAs. Biomolecular Concepts, 8, 119-123.
-
- Alvarez-Dominguez, J. R., & Lodish, H. F. (2017). Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood, 130, 1965-1975.
-
- Amann, K. (2008). Media calcification and intima calcification are distinct entities in chronic kidney disease. Clinical Journal of the American Society of Nephrology, 3, 1599-1605.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous